$MEDP

McCarthy Cornelius P. III sold $465K of MEDP

McCarthy Cornelius P. III sold 795 shares of Medpace Holdings, Inc. (MEDP) at $585.07 ($0.47M total) on 2026-08-07.

Original reporting
SEC EDGAR · McCarthy Cornelius P. III
Published Aug 11, 2026, 8:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 9:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MEDP
Neutral
medium confidence
Mentioned
$MEDP
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MEDPNeutralLow
01

Why it matters

The newest information is the specific insider sale size, price, and post-transaction holdings. It does not include any new corporate guidance, contracts, or regulatory/clinical updates.

02

Market read

Traders may monitor insider activity as a sentiment input, but this filing alone is unlikely to drive a major repricing without additional fundamental catalysts.

03

What to watch

The article provides only the sale details, not context such as prior holdings, compensation timing, or whether other insiders sold/bought around the same period.

Relevance 4/10Novelty 3/10Timing: filed Aug 11, 2026 after-hours (Form 4 timestamp)

Background

The article is a SEC Form 4 insider transaction disclosure for Medpace Holdings, Inc.

Company-level read

Ticker impact

$MEDPNeutralMedium confidence
Context

Medpace director McCarthy Cornelius P. III sold 795 shares in an open-market transaction for about $465K, per a newly filed Form 4.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to intraday sentiment around the filing.

Evidence & confidence

The filing is a routine Form 4 insider sale with no 10b5-1 plan stated and no accompanying operational or guidance change disclosed in the text.

Market effects

No sector read-through is provided; this appears company-specific and routine.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for diversification or tax needs; without a stated 10b5-1 plan, the sale still may not signal negative fundamentals.

Key entities

  • Medpace Holdings, Inc.

    Subject of the Form 4 insider sale disclosure (MEDP).

  • McCarthy Cornelius P. III

    Director who sold 795 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ADVBMed

Top Biotech Gainers: ADVB Soars Over 200% In A Week, NVCR, MEDP Report Q2 Results, AGMB In Focus

Biotech gainers highlighted include Advanced Biomed (ADVB), up about 211% this week to $16.78, with no product sales and a recent SEC registration withdrawal. Novocure (NVCR) rose over 28% after Q2 results and raised 2026 revenue guidance to $710M-$725M. Medpace (MEDP) gained 14% on Q2 revenue of $707.3M and 2026 outlook. SciSparc (SPRC) and Agenus (AGEN) also rose; AgomAb (AGMB) gained on upcoming trial readouts.